Loading asset research
NervGen Pharma Corp. Common stock
NGENNasdaq · USD · StocksQuote as of · Exchange session not verified$2.18
+1.16%
Today
NGEN
Loading 1D prices…
Market cap
$234.9M
Volume
559K
52w high
$6.3052w low
$1.58Company profile
NervGen Pharma Corp. Common stock
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Vancouver, BC, United States
Employees
9
Fiscal year end
1231
CIK
1751912
Session & valuation
Open$2.17
Previous close$2.16
Day high$2.23
Day low$2.14
30-day avg. volume540.9K
Outstanding shares79.6M
Diluted EPS-$0.61
Latest annual period
P/E (trailing)-3.58
P/E (forward)-6.40
Price / book18.67
Beta0.73
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| WHWKWhitehawk Therapeutics Inc. Common Stock | $234.3M | $7.1M | -288.26% | -$0.33 | +0.98% | Buy |
| VRXAVeraxa Biotech AG Ordinary Shares | $233.3M | — | — | -$0.1989 | +0.61% | Unrated |
| NATRNature's Sunshine Products Inc. Common Stock | $238.4M | $480.1M | +4.07% | $1.06 | -0.44% | Buy |
| ADAGAdagene Inc. American Depositary Shares | $228.3M | $7.7M | -229.56% | -$0.30 | +2.72% | Buy |
| GLSIGreenwich LifeSciences Inc. Common Stock | $226.8M | $0.00 | — | -$1.43 | +2.26% | Buy |